Blavatnik Therapeutics Challenge Awards (BTCA) at Harvard Medical School Invests in Exceptional Promise

The Blavatnik Family Foundation’s historic gift to Harvard University has greatly enhanced therapeutics research and development efforts.

Five research projects with the exceptional promise to deliver life-changing and health-altering therapies received the inaugural Blavatnik Therapeutics Challenge Awards (BTCA) at Harvard Medical School. The projects tackle a diverse range of conditions from type 1 diabetes, dementia, congenital immune disease, asthma, and cancer-associated blood clots. Each research project will receive $1 million over two years and active support and guidance from the HMS Translator, a program to advance drug discovery efforts. Funded by the Blavatnik Family Foundation and administered by HMS, the BTCA program aims to accelerate therapeutics research, help investigators navigate the intricacies of intellectual property development and licensing, and spur the creation of new companies.

Read more about the Blavatnik Therapeutics Challenge Awards here.